| Literature DB >> 31119131 |
João Heitor Colombelli Manfrão-Netto1, Antônio Milton Vieira Gomes1, Nádia Skorupa Parachin1.
Abstract
The methylotrophic yeast Hansenula polymorpha, known as a non-conventional yeast, is used for the last 30 years for the production of recombinant proteins, including enzymes, vaccines, and biopharmaceuticals. Although a large number of reviews have been published elucidating the applications of this yeast as a cell factory, the latest was released about 10 years ago. Therefore, this review aimed at summarizing available information on the use of H. polymorpha as a host for recombinant protein production in the last decade. Examples of chemicals and virus-like particles produced using this yeast also are discussed. Firstly, the aspects that feature this yeast as a host for recombinant protein production are highlighted including the techniques available for its genetic manipulation as well as strategies for cultivation in bioreactors. Special attention is given to the novel genomic editing tools, mainly CRISPR/Cas9 that was recently established in this yeast. Finally, recent examples of using H. polymorpha as an expression platform are presented and discussed. The production of human Parathyroid Hormone (PTH) and Staphylokinase (SAK) in H. polymorpha are described as case studies for process establishment in this yeast. Altogether, this review is a guideline for this yeast utilization as an expression platform bringing a thorough analysis of the genetic aspects and fermentation protocols used up to date, thus encouraging the production of novel biomolecules in H. polymorpha.Entities:
Keywords: Hansenula polymorpha; bioprocess; genomic editing; methylotrophic yeast; recombinant protein
Year: 2019 PMID: 31119131 PMCID: PMC6504786 DOI: 10.3389/fbioe.2019.00094
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
Figure 1Main advantages of Hansenula polymorpha as chassi for recombinant protein production include the availability of genetic tools (A,C), thermotolerance (B), ability to use various carbon sources (D), and glycosylation pattern (E).
Recombinant proteins produced in the last decade using H. polymorpha as host.
| Human serum albumin (HSA) | 5.8 g/L | Glycerol/Methanol | Youn et al., | |
| Heat shock protein gp96 | ≈150 mg/L | Methanol | Li et al., | |
| Ferritin (FTH1) | 1.9 g/L | Glycerol/Methanol | Eilert et al., | |
| Bacteriocin enterocin A (EntA) | 4.8 μg/mL | Glucose | Borrero et al., | |
| Granulocyte colony stimulating factor (GCSF) | ND | Methanol | Talebkhan et al., | |
| Streptavidin (SAV) | ≈751 mg/L | Methanol | Wetzel et al., | |
| Human parathyroid hormone (PTH) fragment 1–34 | 150 mg/L | Glycerol/Methanol | Mueller et al., | |
| Penicillin | 1.1 μg/mL | Glucose/Methanol | Gidijala et al., | |
| Human papilomavirus 16 L1 Protein (HPV16L1) | 78.6 mg/L | Methanol | Li et al., | |
| HPV type 16 L1-L2 chimeric protein (SAF) | 132.10 mg/L | Methanol | Bredell et al., | |
| Rabies virus glycoprotein (RVG) | 14.6 mg/L | Glycerol | Qian et al., | |
| Hepatitis B virus PreS2-S antigen | 250 mg/L | Methanol | Xu et al., | |
| Human papillomavirus Type 52 L1 Protein (HPV 52 L1) | ND | Methanol | Liu et al., | |
| Rotavirus VP6 protein (RV VP6) | 3350.71 mg/L | Methanol | Bredell et al., | |
| Hepatitis E virus-like particles (HEV VLPs) | 1.0 g/L | Methanol | Su et al., | |
| Uricase from | 52.3 U/mL | Methanol | Chen et al., | |
| Lipase from | 1,144 U/L | Glucose | Kumari et al., | |
| T4 lysozyme | 0.49 g/L | Glycerol | Wang et al., | |
| Staphylokinase (SAK) | 1,212 mg/L | Glycerol/Methanol | Moussa et al., |
ND, Not Determined.
Most common techniques used for gene deletion in H. polymorpha.
| NCYC495 | 35 | Deletion cassette | 1,000/1,000 | Gonzalez, | |
| NCYC495 | 36 | Deletion cassette | 1,000/1,000 | ||
| NCYC495 Δ | 88 | Deletion cassette | 245/247 | Saraya et al., | |
| NCYC495 | 31 | Deletion cassette | 245/247 | ||
| NCYC495 | 35 | Deletion cassette | 491/520 | Qian et al., | |
| NCYC495 | 76 | Co-transformation with single-stranded DNA | 491/520 | ||
| NCYC495 | 19 | Deletion cassette | ~250/250 | ||
| NCYC495 | 33 | Co-transformation with single-stranded DNA | ~250/250 |
CRISPR/Cas9 systems available for genomic editing in H. polymoprha.
| NCYC495 | 1 | Yes | Episomal | 10−3 | No | Numamoto et al., | ||||
| 1 | Yes | Episomal | 47 | Yes (60/60)bp | ||||||
| 1 | Yes | Episomal | 0.36 | No | ||||||
| 1 | Yes | Episomal | 0.08 | No | ||||||
| 1 | Yes | Episomal | 38 | No | ||||||
| 1 | Yes | Episomal | 45 | No | ||||||
| 4 | Yes | Episomal | 71 | No | ||||||
| 3 | Yes | Episomal | 30 | No | ||||||
| 2 | Yes | Episomal | 67 | No | ||||||
| DL-1 | iCas9 | 1 | Yes | Episomal | 63 ± 2 | ND | Juergens et al., | |||
| iCas9 | 1 | Yes | Episomal | 2-5 | ND | |||||
| CBS4732 | iCas9 | 1 | Yes | Episomal | 9 ± 1 | ND | ||||
| Laboratory strain CGMCC7.89 | iCas9 | 1 | No | Integrative | 58.33 ± 7.22 | Yes (1,000/1,000)bp | Wang et al., | |||
| iCas9 | 1 | No | Integrative | 65.28 ± 2.41 | Yes (1,000/1,000)bp | |||||
| iCas9 | 1 | No | Integrative | 62.18 | Yes (1,000/1,000)bp | |||||
| iCas9 | 1 | No | Integrative | 37.18 | Yes (500/500)bp | |||||
| iCas9 | 1 | No | Integrative | 23.61 | Yes (1,000/1,000)bp | |||||
| iCas9 | 1 | No | Integrative | 75 | Yes (1,000/1,000)bp |
ND* No difference was observed in deletion efficiency with or without HR donor.